Navigation Links
Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
Date:6/7/2013

New York, New York (PRWEB) June 07, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective drugs, has filed a lawsuit on behalf of a Pennsylvania man who allegedly developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, he was diagnosed with bladder cancer. The suit alleges that Actos caused the bladder cancer due to its defective nature. Furthermore, the suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests. The Plaintiff is alleging that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk*. Additional research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal*** found that patients taking the medication were 22 percent more likely to get bladder cancer.
*http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm
**(http://www.bmj.com/content/344/bmj.e3645)
***(http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/Actos_Kasper/06/prweb10814002.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Parker Waichman LLP’s Jordan Chaikin Is Appointed to the Executive Committee of the Plaintiff’s Leadership Team in Emerson Electric Co. Wet/Dry Vac Litigation
3. Woman with Bilateral DePuy Pinnacle Hip Implant Alleges Metal Hips are Flawed in Lawsuit Filed by Parker Waichman LLP
4. Atlantic City Hotel’s Negligence Caused Conditions that Led to Serious Injuries, Alleges Lawsuit Filed by Parker Waichman LLP
5. Parker Waichman LLP Files Appeal over the Pennsylvania Department of Environmental Protection’s Ruling that Natural Gas Wells Did not Harm Couple's Drinking Water Supply
6. Parker Waichman LLP Designated as Co-Lead Counsel in the Consolidation of Hurricane Sandy-related Litigation Against the Long Island Power Authority and/or National Grid
7. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
8. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
9. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
10. DePuy Pinnacle Hip Implant Caused Elevated Ion Levels, Revision Surgery, Alleges Lawsuit Filed by Parker Waichman LLP
11. DePuy ASR Lawsuit Update: Parker Waichman LLP Commends Judge’s Refusal of Appeal for New Trial; DePuy Still Must Pay $8.3 Million Verdict
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: